Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib-Melphalan vs Melphalan Conditioning in MM
NCT02197221Phase 3Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jan 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
A Phase 3 trial of bortezomib in multiple myeloma (MM), sponsored by Centre hospitalier universitaire de Toulouse. Started Jan 2015; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02197221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02197221.